vs
ADMA BIOLOGICS, INC.（ADMA）与Repay Holdings Corp（RPAY）财务数据对比。点击上方公司名可切换其他公司
ADMA BIOLOGICS, INC.的季度营收约是Repay Holdings Corp的1.8倍（$139.2M vs $78.6M），ADMA BIOLOGICS, INC.净利率更高（35.5% vs -178.3%，领先213.8%），ADMA BIOLOGICS, INC.同比增速更快（18.4% vs 0.4%），ADMA BIOLOGICS, INC.自由现金流更多（$34.6M vs $23.2M），过去两年ADMA BIOLOGICS, INC.的营收复合增速更高（30.4% vs -1.3%）
ADMA生物制剂公司是一家专注于研发、生产及商业化特种血浆来源免疫球蛋白疗法的生物制药企业，主要面向美国市场，为原发性免疫缺陷及其他免疫相关疾病患者、医护人员和医疗机构提供免疫健康领域的治疗方案。
Repay Holdings Corp是一家聚焦北美市场的支付技术服务商，为零售、医疗、汽车服务、电商等领域的企业提供整合支付处理方案，涵盖银行卡收单、ACH转账、POS系统集成等数字化支付工具，助力客户简化交易流程、提升运营效率。
ADMA vs RPAY — 直观对比
营收规模更大
ADMA
是对方的1.8倍
$78.6M
营收增速更快
ADMA
高出18.0%
0.4%
净利率更高
ADMA
高出213.8%
-178.3%
自由现金流更多
ADMA
多$11.3M
$23.2M
两年增速更快
ADMA
近两年复合增速
-1.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $139.2M | $78.6M |
| 净利润 | $49.4M | $-140.1M |
| 毛利率 | 63.8% | 74.2% |
| 营业利润率 | 45.1% | -182.2% |
| 净利率 | 35.5% | -178.3% |
| 营收同比 | 18.4% | 0.4% |
| 净利润同比 | -55.9% | -3304.1% |
| 每股收益（稀释后） | $0.20 | $-1.68 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ADMARPAY
| Q4 25 | $139.2M | $78.6M | ||
| Q3 25 | $134.2M | $77.7M | ||
| Q2 25 | $122.0M | $75.6M | ||
| Q1 25 | $114.8M | $77.3M | ||
| Q4 24 | $117.5M | $78.3M | ||
| Q3 24 | $119.8M | $79.1M | ||
| Q2 24 | $107.2M | $74.9M | ||
| Q1 24 | $81.9M | $80.7M |
净利润ADMARPAY
| Q4 25 | $49.4M | $-140.1M | ||
| Q3 25 | $36.4M | $-6.4M | ||
| Q2 25 | $34.2M | $-102.3M | ||
| Q1 25 | $26.9M | $-7.9M | ||
| Q4 24 | $111.9M | $-4.1M | ||
| Q3 24 | $35.9M | $3.2M | ||
| Q2 24 | $32.1M | $-4.1M | ||
| Q1 24 | $17.8M | $-5.2M |
毛利率ADMARPAY
| Q4 25 | 63.8% | 74.2% | ||
| Q3 25 | 56.3% | 74.4% | ||
| Q2 25 | 55.1% | 75.7% | ||
| Q1 25 | 53.2% | 75.9% | ||
| Q4 24 | 53.9% | 76.3% | ||
| Q3 24 | 49.8% | 77.8% | ||
| Q2 24 | 53.6% | 78.2% | ||
| Q1 24 | 47.8% | 76.2% |
营业利润率ADMARPAY
| Q4 25 | 45.1% | -182.2% | ||
| Q3 25 | 38.0% | -3.9% | ||
| Q2 25 | 35.1% | -138.7% | ||
| Q1 25 | 30.4% | -4.7% | ||
| Q4 24 | 32.6% | -1.5% | ||
| Q3 24 | 33.1% | -0.9% | ||
| Q2 24 | 36.6% | -4.6% | ||
| Q1 24 | 26.7% | -3.1% |
净利率ADMARPAY
| Q4 25 | 35.5% | -178.3% | ||
| Q3 25 | 27.1% | -8.3% | ||
| Q2 25 | 28.1% | -135.2% | ||
| Q1 25 | 23.4% | -10.3% | ||
| Q4 24 | 95.2% | -5.3% | ||
| Q3 24 | 30.0% | 4.1% | ||
| Q2 24 | 29.9% | -5.4% | ||
| Q1 24 | 21.7% | -6.5% |
每股收益（稀释后）ADMARPAY
| Q4 25 | $0.20 | $-1.68 | ||
| Q3 25 | $0.15 | $-0.08 | ||
| Q2 25 | $0.14 | $-1.15 | ||
| Q1 25 | $0.11 | $-0.09 | ||
| Q4 24 | $0.45 | $-0.04 | ||
| Q3 24 | $0.15 | $0.03 | ||
| Q2 24 | $0.13 | $-0.04 | ||
| Q1 24 | $0.08 | $-0.06 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $87.6M | $115.7M |
| 总债务越低越好 | $72.1M | $280.1M |
| 股东权益账面价值 | $477.3M | $484.4M |
| 总资产 | $624.2M | $1.2B |
| 负债/权益比越低杠杆越低 | 0.15× | 0.58× |
8季度趋势，按日历期对齐
现金及短期投资ADMARPAY
| Q4 25 | $87.6M | $115.7M | ||
| Q3 25 | $61.4M | $95.7M | ||
| Q2 25 | $90.3M | $162.6M | ||
| Q1 25 | $71.6M | $165.5M | ||
| Q4 24 | $103.1M | $189.5M | ||
| Q3 24 | $86.7M | $168.7M | ||
| Q2 24 | $88.2M | $147.1M | ||
| Q1 24 | $45.3M | $128.3M |
总债务ADMARPAY
| Q4 25 | $72.1M | $280.1M | ||
| Q3 25 | $72.4M | $279.5M | ||
| Q2 25 | — | $279.0M | ||
| Q1 25 | — | $497.6M | ||
| Q4 24 | $72.3M | $496.8M | ||
| Q3 24 | — | $496.2M | ||
| Q2 24 | — | $435.6M | ||
| Q1 24 | — | $434.9M |
股东权益ADMARPAY
| Q4 25 | $477.3M | $484.4M | ||
| Q3 25 | $431.2M | $616.9M | ||
| Q2 25 | $398.3M | $633.7M | ||
| Q1 25 | $373.4M | $755.7M | ||
| Q4 24 | $349.0M | $761.3M | ||
| Q3 24 | $231.9M | $754.7M | ||
| Q2 24 | $188.3M | $815.4M | ||
| Q1 24 | $153.7M | $813.8M |
总资产ADMARPAY
| Q4 25 | $624.2M | $1.2B | ||
| Q3 25 | $568.7M | $1.3B | ||
| Q2 25 | $558.4M | $1.4B | ||
| Q1 25 | $510.6M | $1.5B | ||
| Q4 24 | $488.7M | $1.6B | ||
| Q3 24 | $390.6M | $1.6B | ||
| Q2 24 | $376.4M | $1.5B | ||
| Q1 24 | $350.9M | $1.5B |
负债/权益比ADMARPAY
| Q4 25 | 0.15× | 0.58× | ||
| Q3 25 | 0.17× | 0.45× | ||
| Q2 25 | — | 0.44× | ||
| Q1 25 | — | 0.66× | ||
| Q4 24 | 0.21× | 0.65× | ||
| Q3 24 | — | 0.66× | ||
| Q2 24 | — | 0.53× | ||
| Q1 24 | — | 0.53× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $35.6M | $23.3M |
| 自由现金流经营现金流 - 资本支出 | $34.6M | $23.2M |
| 自由现金流率自由现金流/营收 | 24.8% | 29.6% |
| 资本支出强度资本支出/营收 | 0.8% | 0.1% |
| 现金转化率经营现金流/净利润 | 0.72× | — |
| 过去12个月自由现金流最近4个季度 | $27.8M | $90.7M |
8季度趋势，按日历期对齐
经营现金流ADMARPAY
| Q4 25 | $35.6M | $23.3M | ||
| Q3 25 | $13.3M | $32.2M | ||
| Q2 25 | $21.1M | $33.1M | ||
| Q1 25 | $-19.7M | $2.5M | ||
| Q4 24 | $50.2M | $34.3M | ||
| Q3 24 | $25.0M | $60.1M | ||
| Q2 24 | $45.6M | $31.0M | ||
| Q1 24 | $-2.2M | $24.8M |
自由现金流ADMARPAY
| Q4 25 | $34.6M | $23.2M | ||
| Q3 25 | $-1.1M | $32.1M | ||
| Q2 25 | $18.7M | $33.0M | ||
| Q1 25 | $-24.4M | $2.4M | ||
| Q4 24 | $47.5M | $34.0M | ||
| Q3 24 | $24.0M | $59.8M | ||
| Q2 24 | $43.6M | $30.5M | ||
| Q1 24 | $-4.6M | $24.7M |
自由现金流率ADMARPAY
| Q4 25 | 24.8% | 29.6% | ||
| Q3 25 | -0.8% | 41.3% | ||
| Q2 25 | 15.3% | 43.6% | ||
| Q1 25 | -21.2% | 3.0% | ||
| Q4 24 | 40.4% | 43.5% | ||
| Q3 24 | 20.0% | 75.6% | ||
| Q2 24 | 40.7% | 40.7% | ||
| Q1 24 | -5.6% | 30.6% |
资本支出强度ADMARPAY
| Q4 25 | 0.8% | 0.1% | ||
| Q3 25 | 10.7% | 0.2% | ||
| Q2 25 | 2.0% | 0.1% | ||
| Q1 25 | 4.1% | 0.2% | ||
| Q4 24 | 2.3% | 0.3% | ||
| Q3 24 | 0.9% | 0.3% | ||
| Q2 24 | 1.9% | 0.6% | ||
| Q1 24 | 2.9% | 0.1% |
现金转化率ADMARPAY
| Q4 25 | 0.72× | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.62× | — | ||
| Q1 25 | -0.73× | — | ||
| Q4 24 | 0.45× | — | ||
| Q3 24 | 0.70× | 18.52× | ||
| Q2 24 | 1.42× | — | ||
| Q1 24 | -0.12× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
RPAY
| Sales Channel Directly To Consumer | $69.4M | 88% |
| Other | $6.8M | 9% |
| Sales Channel Through Intermediary | $2.3M | 3% |
